Chemosensitivity testing in XXXX .

@entity1 @entity23974 @entity5 @entity21193 @entity2974 @entity1311 @entity900 @entity10051 @entity3 @entity136 @entity320 @entity855
The prognosis of @entity1 with @entity320 remains poor. In @entity1 with distant metastases only low response rates between 10% and 15% have been achieved by the most effective cytostatics in single-agent therapy leading to a mean 5-year survival rate of less than 5%. More aggressive treatment regimens using multidrug chemotherapy yielded response rates of up to 40% but failed to show a significant benefit in overall survival compared to single-agent therapy. However, complete remissions of @entity3 after multidrug cytostatic regimens have been reported in some cases of @entity320 @entity1 . To evaluate an in vitro test system providing information on the drug sensitivity profile of @entity320 cells, we examined @entity5 tissue specimens from 31 @entity320 @entity1 with an @entity855 -based chemosensitivity assay ( @entity855 - @entity2974 ) testing eight anticancer drugs alone or in different combinations. Chemosensitivity was assessed using a @entity10051 -luciferase- based luminescence assay providing individual chemosensitivity indices for each test drug. We found a heterogeneous chemosensitivity in the @entity320 tissue samples tested. The highest sensitivity was detected for the combination of @entity21193 and @entity136 , with 76% of the tissue samples revealing high sensitivity and 10% resistance, followed by the combination of @entity1311 and @entity23974 (66%/0%), @entity136 and @entity900 (55%/21%),and @entity1311 and @entity900 (46%/8%). Our data indicate that the @entity855 - @entity2974 can be used to select @entity1 who might benefit from an individually adapted cytostatic therapy. On the basis of these results a multicenter trial has recently been initiated to evaluate the feasibility and predictive value of an @entity855 - @entity2974 directed chemotherapy in @entity320 @entity1 .
